December 1, 2012
By:
Kevin Murphy, Andrew Nason
Can postapproval FDA filings immunize pharma companies from patent lawsuits?
|
October 1, 2012
By:
David L. Rosen
Do you have to worry about FDA releasing confidential data? Apparently so.
|
September 1, 2012
By:
Jim Greenwood
Ties between the biotechnology industry and university research are crucial.
|
June 1, 2012
By:
Michiel E. Ultee, PhD
Formulators and developers are at the heart of the industry's basic premise—they are saving lives.
|
May 1, 2012
By:
Nancy Gillett
Future sponsor-contract provider relationships will require more integration.
|
April 1, 2012
By:
Rita E. Numerof, Michael N. Abrams
Rather than seeking a single indication for one large group, the orphan-drug approach segments the market for a drug more minutely.
|
March 1, 2012
By:
Fiona Greer
Does global development have to entail multiple comparability studies?
|
February 1, 2012
By:
Frances J. Richmond
New educational programs are key to the industry's future and to safe, available drugs.
|
|
